Revolution Medicines Details 2026 Operating Expenses and Clinical Trial Expansion

Revolution Medicines projected $1.7 billion to $1.8 billion in GAAP operating expenses for 2026 and announced the expansion of its RASolve 301 clinical trial to include 590 patients.